In Canada next year Semaglutide (which is what is in Ozempic and I think is what people call a GLP-1 but I am no expert that's for sure) comes off patent protection.
Today on the news they said the 3 big generic companies here are in the works to get approval for their generic versions.
The reporter said pricing should likely come down to around $75 per month. Thinking when this happens it is going to become very popular.
(cut and past below)
Key Patent Expiry Timelines
- 2026 (Major Markets):
Semaglutide patents start expiring in Canada (Jan 2026), India, and China, allowing generic manufacturers to enter these large populations.
- 2027 (US):
The patent for Eli Lilly's older GLP-1 drug, Trulicity (dulaglutide), is set to expire.
- Early 2030s (US/EU):
The core semaglutide compound patent, despite extensions, is expected to expire in the US and EU around 2031, allowing for biosimilar/generic competition later in the decade.
Impact of Expirations
Lower Costs: Generic semaglutide will significantly reduce treatment costs.
Increased Access: More affordable options will reach millions with diabetes and obesity.
Market Shift: Generics from Indian and other manufacturers will drive competition.
Specific Example: Canada
Novo Nordisk's primary semaglutide patent lapsed in Canada in 2025 (after failing to pay maintenance fees), with regulatory exclusivity expiring in early 2026, enabling immediate generic entry.
Broader Context
These expirations are a major event for the multi-billion dollar GLP-1 market, following years of high demand and high prices for branded drugs.